Denali Therapeutics, Inc. is a US-based pharmaceutical company with a medium-risk ESG score of 24.9. Specializing in biotechnology, Denali focuses on developing innovative therapies to combat neurodegenerative diseases. Their LRRK2 Inhibitor Program aims to create brain-penetrant products for Parkinson's Disease. Notable products in their pipeline include DNL201, DNL151, DNL747, ATV, and ETV.